Skip to main content

Table 8 Medium-resolution HLA-A genotyping: status of common alleles by clinical activity status: all response-evaluable patients with medium-resolution HLA genotype data.

From: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Allele* Clinical Activity Status n (%)
   Allele Present Allele Absent Allele status unknown Total
02 Benefit 8 (72.7) 3 (27.3) 1 (8.3) 12 (17.9)
  Non-Benefit 28 (65.1) 15 (34.9) 3 (6.5) 46 (68.7)
  Unknown 3 (37.5) 5 (62.5) 1 (11.1) 9 (13.4)
24 Benefit 1 (10.0) 9 (90.0) 2 (16.7) 12 (17.9)
  Non-Benefit 12 (28.6) 30 (71.4) 4 (8.7) 46 (68.7)
  Unknown 2 (25.0) 6 (75.0) 1 (11.1) 9 (13.4)
03 Benefit 2 (20.0) 8 (80.0) 2 (16.7) 12 (17.9)
  Non-Benefit 9 (21.4) 33 (78.6) 4 (8.7) 46 (68.7)
  Unknown 2 (25.0) 6 (75.0) 1 (11.1) 9 (13.4)
01 Benefit 1 (16.7) 5 (83.3) 6 (50.0) 12 (17.9)
  Non-Benefit 8 (20.5) 31 (79.5) 7 (15.2) 46 (68.7)
  Unknown 2 (28.6) 5 (71.4) 2 (22.2) 9 (13.4)
11 Benefit 2 (20.0) 8 (80.0) 2 (16.7) 12 (17.9)
  Non-Benefit 6 (14.3) 36 (85.7) 4 (8.7) 46 (68.7)
  Unknown 1 (12.5) 7 (87.5) 1 (11.1) 9 (13.4)
  1. *Only alleles present in at least 10% of all patients are shown.
  2. Denominator for percents in columns "Allele Present" and "Allele Absent" is number of patients in row with known allele status.
  3. Denominator for percents in column "Allele Status Unknown" is row total.
  4. Denominator for percents in column "Total" is 67, the total number of patients in the data set.